Santhera Pharmaceuticals Holding AG
SIX:SANN
Income Statement
Earnings Waterfall
Santhera Pharmaceuticals Holding AG
Revenue
|
5.2m
CHF
|
Cost of Revenue
|
-3.6m
CHF
|
Gross Profit
|
1.5m
CHF
|
Operating Expenses
|
-48.3m
CHF
|
Operating Income
|
-46.7m
CHF
|
Other Expenses
|
-17.9m
CHF
|
Net Income
|
-64.7m
CHF
|
Income Statement
Santhera Pharmaceuticals Holding AG
Sep-2018 | Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Revenue |
30
N/A
|
32
+5%
|
42
+31%
|
75
+81%
|
65
-14%
|
15
-77%
|
12
-22%
|
(2)
N/A
|
0
N/A
|
7
+4 485%
|
5
-31%
|
|
Gross Profit | ||||||||||||
Cost of Revenue |
(5)
|
(5)
|
(6)
|
(5)
|
(5)
|
(10)
|
(10)
|
(4)
|
(4)
|
(4)
|
(4)
|
|
Gross Profit |
26
N/A
|
27
+6%
|
36
+32%
|
70
+97%
|
60
-14%
|
5
-92%
|
1
-70%
|
(5)
N/A
|
(3)
+36%
|
4
N/A
|
2
-61%
|
|
Operating Income | ||||||||||||
Operating Expenses |
(79)
|
(78)
|
(94)
|
(80)
|
(74)
|
(58)
|
(48)
|
(52)
|
(60)
|
(56)
|
(48)
|
|
Selling, General & Administrative |
(43)
|
(40)
|
(47)
|
(39)
|
(34)
|
(24)
|
(18)
|
(22)
|
(27)
|
(25)
|
(25)
|
|
Research & Development |
(35)
|
(38)
|
(47)
|
(41)
|
(40)
|
(34)
|
(30)
|
(30)
|
(33)
|
(31)
|
(23)
|
|
Other Operating Expenses |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(53)
N/A
|
(51)
+4%
|
(58)
-14%
|
(10)
+82%
|
(14)
-33%
|
(53)
-282%
|
(47)
+12%
|
(57)
-22%
|
(63)
-11%
|
(52)
+18%
|
(47)
+10%
|
|
Pre-Tax Income | ||||||||||||
Interest Income Expense |
(3)
|
(2)
|
(7)
|
(8)
|
(9)
|
(6)
|
(12)
|
(8)
|
(1)
|
(21)
|
(20)
|
|
Total Other Income |
0
|
(0)
|
0
|
0
|
(1)
|
(8)
|
3
|
10
|
(0)
|
2
|
2
|
|
Pre-Tax Income |
(57)
N/A
|
(54)
+5%
|
(65)
-21%
|
(18)
+72%
|
(23)
-27%
|
(67)
-189%
|
(56)
+17%
|
(55)
+2%
|
(64)
-17%
|
(71)
-10%
|
(65)
+8%
|
|
Net Income | ||||||||||||
Tax Provision |
(2)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
|
Income from Continuing Operations |
(58)
|
(54)
|
(66)
|
(19)
|
(24)
|
(68)
|
(56)
|
(56)
|
(65)
|
(71)
|
(65)
|
|
Net Income (Common) |
(58)
N/A
|
(54)
+7%
|
(66)
-22%
|
(19)
+71%
|
(24)
-26%
|
(68)
-183%
|
(56)
+17%
|
(56)
+1%
|
(65)
-17%
|
(71)
-10%
|
(65)
+9%
|
|
EPS (Diluted) |
-8.96
N/A
|
-7.86
+12%
|
-6.08
+23%
|
-1.73
+72%
|
-2.08
-20%
|
-50.81
-2 343%
|
-2.53
+95%
|
-16.27
-543%
|
-11.42
+30%
|
-11.67
-2%
|
-57.96
-397%
|